Journal of NeuroVirology

, Volume 17, Issue 3, pp 288–290

Natalizumab and HSV meningitis

  • Erica Seiguer Shenoy
  • Eleftherios Mylonakis
  • Rocio M. Hurtado
  • Nagagopal Venna
Case Report

DOI: 10.1007/s13365-011-0027-4

Cite this article as:
Shenoy, E.S., Mylonakis, E., Hurtado, R.M. et al. J. Neurovirol. (2011) 17: 288. doi:10.1007/s13365-011-0027-4

Abstract

Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn’s disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.

Copyright information

© Journal of NeuroVirology, Inc. 2011

Authors and Affiliations

  • Erica Seiguer Shenoy
    • 1
    • 3
  • Eleftherios Mylonakis
    • 1
    • 3
  • Rocio M. Hurtado
    • 1
    • 3
  • Nagagopal Venna
    • 2
  1. 1.Division of Infectious DiseasesMassachusetts General HospitalBostonUSA
  2. 2.Department of NeurologyMassachusetts General HospitalBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA